AdultPediatricDosage Forms & Strengths tiotropium bromide/olodaterol inhaled inhalation spray (3.124mcg/2.736mcg)/actuation (equivalent to 2.5mcg/2.5mcg) Chronic Obstructive Pulmonary Disease Indicated for long-term, once-daily maintenance treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema Inhale 2 actuations PO qDay at the same time of the day Dosage Modifications Renal impairment No dosage adjustment required Moderate-to-severe (≤60 mL/min): Monitor closely for anticholinergic adverse effects Hepatic impairment Mild-to-moderate: No dose adjustment required Severe: Not studied Dosing Considerations Not indicated to treat acute deteriorations of COPD Not indicated to treat asthmaSafety and efficacy not establishedInteraction CheckerEnter a drug name and tiotropium/olodaterol inhaledNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)umeclidinium bromide/vilanterol inhaledtiotropium, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Duplicate therapy.Serious - Use Alternative (7)amisulprideamisulpride and olodaterol inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.chloroquinechloroquine and olodaterol inhaled both increase QTc interval. Avoid or Use Alternate Drug.fexinidazolefexinidazole and olodaterol inhaled both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.glucagonglucagon increases toxicity of tiotropium by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .glucagon intranasalglucagon intranasal increases toxicity of tiotropium by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .lefamulinlefamulin and olodaterol inhaled both increase QTc interval. Avoid or Use Alternate Drug.pramlintidepramlintide, tiotropium. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.Monitor Closely (225)abirateroneabiraterone and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasabobotulinumtoxinAabobotulinumtoxinA increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .acebutololacebutolol, olodaterol inhaled. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Beta-blockers and olodaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.albuterolalbuterol and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsalbuterol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.alfuzosinalfuzosin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasamantadinetiotropium, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.amiodaroneamiodarone and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasamitriptylineamitriptyline and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiastiotropium and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapineamoxapine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiastiotropium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.apomorphineapomorphine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasarformoterolarformoterol and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsarformoterol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.aripiprazolearipiprazole and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.tiotropium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.tiotropium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.aripiprazole increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.arsenic trioxidearsenic trioxide and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasatracuriumatracurium and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.artemetherartemether and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasasenapineasenapine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasasenapine transdermalasenapine transdermal and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasatomoxetineatomoxetine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.atropineatropine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.atropine IV/IMatropine IV/IM and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.azithromycinazithromycin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasbelladonna alkaloidsbelladonna alkaloids and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opiumbelladonna and opium and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.bendroflumethiazidebendroflumethiazide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.benperidoltiotropium decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.tiotropium decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.benperidol increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benztropinebenztropine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. betamethasonebetamethasone and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.bethanecholbethanechol increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.bosutinibbosutinib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.bumetanidebumetanide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.capecitabinecapecitabine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.carbacholcarbachol increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carvedilolcarvedilol, olodaterol inhaled. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor. Beta-blockers and olodaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.ceritinibceritinib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.cevimelinecevimeline increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorothiazidechlorothiazide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.chlorpromazinechlorpromazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tiotropium decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiastiotropium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.chlorthalidonechlorthalidone and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.cisatracuriumcisatracurium and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.ciprofloxacinciprofloxacin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiascitalopramcitalopram and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasclarithromycinclarithromycin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasclomipramineclomipramine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiastiotropium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clozapinetiotropium decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.clozapine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.tiotropium decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.clozapine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.corticotropincorticotropin and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.cyclizinecyclizine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.cortisonecortisone and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.crizotinibcrizotinib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.cyclobenzaprinecyclobenzaprine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiascyclobenzaprine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.darifenacindarifenacin and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.dasatinibdasatinib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdegarelixdegarelix and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdesipraminedesipramine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiastiotropium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.deutetrabenazinedeutetrabenazine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dicyclominedicyclomine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.dexamethasonedexamethasone and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.dichlorphenamidedichlorphenamide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.diphenhydraminediphenhydramine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.disopyramidedisopyramide and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdobutaminedobutamine and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsdofetilidedofetilide and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdolasetrondolasetron and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdonepezildonepezil and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.donepezil increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil transdermaldonepezil transdermal, tiotropium. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dopaminedopamine and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsdosulepintiotropium and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepintiotropium and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong